Akebia Therapeutics, Inc. (AKBA)
$
1.51
+0.05 (3.31%)
Key metrics
Financial statements
Free cash flow per share
0.2548
Market cap
404.5 Million
Price to sales ratio
1.7126
Debt to equity
6.6329
Current ratio
1.1344
Income quality
-12.7207
Average inventory
9.3 Million
ROE
-0.1670
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with kidney diseases. The company's lead investigational product candidate, vadadustat, is an oral therapy currently in Phase III trials aimed at treating anemia caused by chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent adult patients. Additionally, Akebia provides Auryxia, a ferric citrate medication that helps control serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease (DD-CKD) and addresses iron deficiency anemia in those not on dialysis. The weighted average number of diluted shares outstanding is 257,157,782.00 reflecting potential dilution effects, while the company’s stock is identified with the symbol 'AKBA' in the market. Akebia has established collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat across a broad range of regions, including the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries. Furthermore, it has partnered with Mitsubishi Tanabe Pharma Corporation for similar efforts in Japan and other Asian markets. Akebia also maintains a research and license agreement with Janssen Pharmaceutica NV to advance hypoxia-inducible factor prolyl hydroxylase targeted compounds on a global scale. The company earned an interest income of $0.00 showcasing its financial investments, and incurred an income tax expense of $1,624,000.00 indicating its tax obligations. The net income ratio is -0.02 reflecting the company's profitability margin. The company's stock is affordable at $2.82 making it an appealing option for budget-conscious investors. Additionally, the stock has a high average trading volume of 3,273,362.00 indicating strong liquidity. With a market capitalization of $404,497,290.00 the company is classified as a small-cap player in the industry. Akebia Therapeutics is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.
Is Akebia Therapeutics, Inc. (AKBA) a good investment?
Investing in Akebia Therapeutics, Inc. (AKBA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bullish outlook. Always conduct your own research before investing.
What is Akebia Therapeutics, Inc. (AKBA)'s stock forecast?
Analysts predict Akebia Therapeutics, Inc. stock to fluctuate between $1.14 (low) and $4.08 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Akebia Therapeutics, Inc.'s market capitalization?
As of 2026-03-17, Akebia Therapeutics, Inc.'s market cap is $404,497,290, based on 267,879,000 outstanding shares.
How does Akebia Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Akebia Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Akebia Therapeutics, Inc. (AKBA) stock?
To buy Akebia Therapeutics, Inc. (AKBA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for AKBA. Place an order (Market, Limit, etc.).
What is the best time to invest in Akebia Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Akebia Therapeutics, Inc. perform in the last earnings report?
Revenue: $236,196,000 | EPS: -$0.02 | Growth: -93.70%.
Where can I find Akebia Therapeutics, Inc.'s investor relations reports?
Visit https://www.akebia.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Akebia Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Akebia Therapeutics, Inc. stock?
All-time high: $4.08 (2025-07-11) | All-time low: $0.24 (2022-10-24).
What are the key trends affecting Akebia Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
defenseworld.net
Akebia Therapeutics (NASDAQ: AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic evidence for broader adoption, and outline pipeline plans in rare kidney disease. Management reported $227 million in combined 2025 net product revenue from Vafseo (vadadustat) and Auryxia,
seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Q4 2025 Earnings Call Transcript
seekingalpha.com
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript
seekingalpha.com
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts
defenseworld.net
Assenagon Asset Management S.A. acquired a new stake in shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 426,766 shares of the biopharmaceutical company's stock, valued at approximately $1,165,000.
zacks.com
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
seekingalpha.com
Akebia Therapeutics, Inc. ( AKBA ) Q3 2025 Earnings Call November 10, 2025 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler - CEO, President & Director Nicholas Grund - Senior VP & Chief Commercial Officer Erik Ostrowski - Chief Business Officer, Senior VP, CFO & Treasurer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division Andrew Kassin - BTIG, LLC, Research Division Matthew Caufield - H.C. Wainwright & Co, LLC, Research Division Jiale Song - Jefferies LLC, Research Division Presentation Operator Good day, and thank you for standing by.
globenewswire.com
Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025
benzinga.com
Akebia Therapeutics Inc. (NASDAQ:AKBA) stock is trading lower on Wednesday.
See all news
